Editorial
The hunt for fatal myocardial infarction biomarkers: predictive circulating microRNAs
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S1
(October 2016)
Acquisition of carbapenem-resistant Acinetobacter baumannii in the intensive care unit: just a question of time?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S2
(October 2016)
Another promise against ischemia reperfusion injury: every success raises new questions
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S3
(October 2016)
Live-attenuated vaccination increases the diversity of pathogen-specific T cell repertoire triggered in chronic infection responses
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S4
(October 2016)
Immunotherapy in small-cell lung cancer: at what point are we?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S5
(October 2016)
Is macitentan not a treatment option for digital ulcers in systemic sclerosis?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S6
(October 2016)
The AMPK-SKP2-CARM1 axis links nutrient sensing to transcriptional and epigenetic regulation of autophagy
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S7
(October 2016)
Sofosbuvir and velpatasvir: a stellar option for patients with decompensated hepatitis C virus (HCV) cirrhosis
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S8
(October 2016)
Immune checkpoint inhibition in patients with brain metastases
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S9
(October 2016)
Osteoporosis and strontium-substituted hydroxyapatites
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S10
(October 2016)
Na+ homeostasis by epithelial Na+ channel (ENaC) and Nax channel (Nax): cooperation of ENaC and Nax
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S11
(October 2016)
C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S12
(October 2016)
Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4–5 chronic kidney disease
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S13
(October 2016)
ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S14
(October 2016)
A liberal glycemic target in critically ill patients with poorly controlled diabetes?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S15
(October 2016)
Can xerostomia be further reduced by sparing parotid stem cells?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S16
(October 2016)
Transapical beating-heart mitral valve repair using a cordal implantation device—are we ready to open our minds?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S17
(October 2016)
The role of glutamate transport and SLC7A11 expression in tumor-associate seizures and survival in patients with malignant gliomas
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S18
(October 2016)
Modifying therapy in patients with advanced Hodgkin’s lymphoma by integrating early metabolic response by interim PET-CT
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S19
(October 2016)
A canine model for neuronal ceroid lipofuscinosis highlights the promise of gene therapy for lysosomal storage diseases
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S20
(October 2016)
The Ross procedure is under-used although long-term results show superior results to those obtained following mechanical aortic valve replacement
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S21
(October 2016)
Hospital-acquired pneumonia and community-acquired pneumonia: two guys?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S22
(October 2016)
Connecting enterovirus infection to dystrophin dysfunction in dilated cardiomyopathy
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S23
(October 2016)
Tumor vaccines and cellular immunotherapies
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S24
(October 2016)
Measuring soluble CD40 ligand: it is a fancy prognostic biomarker in STEMI-patients?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S25
(October 2016)
The case for preoperative aspirin administration in patients undergoing elective CABG: is it open or closed?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S26
(October 2016)
Interventional therapies in ischemic ventricular dysfunction: facts and versions!
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S27
(October 2016)
Towards a cure for Fibrodysplasia ossificans progressiva
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S28
(October 2016)
Narcolepsy and influenza vaccination—the inappropriate awakening of immunity
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S29
(October 2016)
Circulating micro ribonucleic acids in cardiovascular disease: a look beyond myocardial injury
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S30
(October 2016)
Commentary
Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S31
(October 2016)
Rhythm is a dancer: the immediate management of postoperative atrial fibrillation following cardiac surgery
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S32
(October 2016)
Branching pattern of the lateral femoral cutaneous nerve at the proximal thigh: a commentary on a recent published cadaveric study
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S33
(October 2016)
Continuing aspirin before coronary artery bypass grafting surgery: old fears challenged by new evidences
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S34
(October 2016)
The prostate-specific protein, transglutaminase 4 (TG4), is an autoantigen associated with male subfertility
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S35
(October 2016)
Should trochanteric osteotomy be always avoided during safe hip dislocation?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S36
(October 2016)
The anterolateral ligament: a closed chapter?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S37
(October 2016)
Circulating fibrocytes serve as a marker for clinical diagnosis
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S38
(October 2016)
Robotics accuracy in orthopaedics: is it enough for a well-working knee replacement?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S39
(October 2016)
Robotic unicondylar knee arthroplasty: a commentary on a recently published level 1 study
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S40
(October 2016)
The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S41
(October 2016)
The emerging role of sST2 blocking in the therapy of graft-versus-host disease
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S42
(October 2016)
Time to progression ratio: promising new metric or just another metric?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S43
(October 2016)
PTK2/FAK: a new predictive biomarker for response to radiotherapy in head and neck squamous cell carcinoma
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S44
(October 2016)
Azoramide: a new drug for the treatment of type 2 diabetes?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S45
(October 2016)
Severe ischemic cardiomyopathy—a new answer in management?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S46
(October 2016)
Vasopressin versus noradrenaline as initial therapy in septic shock. Is vasopressin-related renal protection doomed to “vanish” in the haze?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S47
(October 2016)
Statins barely touch the heart but bite the kidneys after cardiac surgery. Coenzyme Q10 deficiency in the dock?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S48
(October 2016)
Less invasive approach in knee arthroplasty: everybody on board?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S49
(October 2016)
Collagen and fibronectin: threads linking obesity and breast cancer
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S50
(October 2016)
Playing with nanoparticle shapes and laser powers to decide which route to take during photothermal therapy: apoptosis or necrosis?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S51
(October 2016)
Hybrid approach to multivessel coronary artery disease: a commentary
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S52
(October 2016)
Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S53
(October 2016)
Magnetic resonance imaging-guided stratified selection of patients for nano-therapy
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S54
(October 2016)
Ischemia-reperfusion injury: evidences for translational research
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S55
(October 2016)
Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S56
(October 2016)
A sensible approach to targeting STAT3-mediated transcription
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S57
(October 2016)
Preclinical randomized controlled multicenter trials in translational stroke research
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S58
(October 2016)
Th2/Th17 reciprocal regulation: twists and turns in the complexity of asthma phenotypes
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S59
(October 2016)
Circulating extracellular vesicles containing miRNAs may have utility as early biomarkers for cardiac injury
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S60
(October 2016)
Precision medicine with electronic medical records: from the patients and for the patients
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S61
(October 2016)
Epidermal growth factor as a prognostic biomarker in chronic kidney diseases
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S62
(October 2016)
Therapeutic illusion: another frontier in Ménière’s disease
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S63
(October 2016)
Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S64
(October 2016)
Second line treatment of small cell lung cancer: more is better?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S65
(October 2016)
Has moderate ischemic mitral regurgitation to be corrected?—Analysis of a randomized trial
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S66
(October 2016)
Did the beneficial renal outcomes with vasopressin VANISH?
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S67
(October 2016)
The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies
Annals of Translational Medicine
2016;
4
(Suppl 1)
:S68
(October 2016)
Disclosure:
The supplement was published without any sponsorship or funding.
